Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.

ABSTRACT:

Importance

Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC).

Objective

To investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan.

Design, setting, and participants

This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022.

Exposure

Tucatinib combined with trastuzumab and capecitabine administered at the recommended dose.

Main outcomes and measures

Clinical end points included progression-free survival

SUBMITTER: Frenel JS 

PROVIDER: S-EPMC10993071 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature